YSCH-01

BIOLOGICAL3 trials

Sponsors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Huashan Hospital

Conditions

Advanced Solid TumorAdvanced Solid TumorsMetastatic Solid TumorsNSCLCRare Malignant NeoplasmRecurrent Glioblastoma

Early Phase 1

Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma

RecruitingNCT07538128

Huashan HospitalRecurrent Glioblastoma

Start: 2025-01-09End: 2027-02-28Target: 10Updated: 2026-04-20

YSCH-01 Via Nebulization in Pulmonary Metastasis of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC)

RecruitingNCT07793500

Cancer Institute and Hospital, Chinese Academy of Medical SciencesNSCLC, Advanced Solid Tumor

Start: 2025-11-27End: 2026-12-30Target: 36Updated: 2026-08-28

Phase 1

Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)

Not yet recruitingNCT07307053

Cancer Institute and Hospital, Chinese Academy of Medical SciencesRare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors

Start: 2026-01-01End: 2031-01-31Target: 600Updated: 2025-12-29